À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾

Ϊ´òÔì³Õ´ôÖ¢Éú̬ϵͳ£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½¨Á¢È«ÐÂÊý×ÖÒµÎñ¹«Ë¾

9ÔÂ13ÈÕ£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÉèÁ¢Êý×Ö»¯ÒµÎñ¹«Ë¾¡ª¡ªTheoria Technologies, Ö¼ÔÚ¼ÓËÙ³Õ´ôÖ¢Éú̬ϵͳµÄ½¨Á¢ºÍÉú³¤¡£Theoria TechnologiesÊÇÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÄÈ«×Ê×Ó¹«Ë¾¡£

ΪÁË»º½â³Õ´ôÖ¢»¼Õß¼°Æä¼ÒÊôµÄ½¹ÂÇ£¬½â¾öÉç»áÎÊÌ⣬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾²»½ö¿ª·¢ÖÎÁƳմôÖ¢µÄÒ©Î»¹Í¨¹ý¿ª·¢Êý×Ö½â¾ö·½°¸ºÍÓëÆäËüÐÐÒµºÏ×÷£¬Å¬Á¦½¨Á¢³Õ´ôÖ¢Éú̬ϵͳ¡£Theoria Technologies½«³ÉΪ¸ß¶È͸Ã÷ºÍÖÐÁ¢µÄ³Õ´ô֢ƽ̨µÄºËÐÄ£¬²¢Îª¿ª·¢Ò»¸öÉú̬ϵͳµì»ù»ù´¡£¬Ê¹³Õ´ôÖ¢»¼ÕßÎÞÂÛÄÄÖÖ¼²²¡ÀàÐÍ»ò´¦ÓÚÄĸö¼²²¡½×¶Î£¬¶¼ÄÜ¡°¹ýÉÏ×î³äʵµÄÉú»î¡±¡£

Theoria Technologies½«ÔÚÊý×Ö»¯ÒµÎñÓÅ»¯µÄ×éÖ¯½á¹¹Ï¼ÓËÙ¾ö²ß£¬¼ÓÇ¿¶ÔÊý×Ö»¯È˲ŵÄÕÐÆ¸ºÍÅàѵ£¬²¢½«ÀûÓÃÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¶àÄê»ýÀÛµÄÁÙ´²Ñо¿Êý¾ÝÒÔ¼°ÐÐÁÐÑо¿Êý¾Ý¡¢¸öÈ˽¡¿µ¼Ç¼(PHR)µÈÊý¾Ý£¬¿ª·¢ÖÖÖÖÔ¤²âËã·¨£¬´´½¨Êý×Ö»¯½â¾ö·½°¸²¢ÌṩÊý¾Ý¡£Theoria Technologies½«ÓÚ2024Äê4Ô¿ªÊ¼ÒµÎñ»î¶¯£¬ÒÔÆÚÓÚ2024²ÆÄêÌṩ·¢ÏÖÔçÆÚÇá¶ÈÈÏÖªÕϰ­£¨MCI£©ºÍ³Õ´ôÖ¢·çÏÕÔ¤²âËã·¨·þÎñ¡£´ËÍ⣬Theoria Technologies½«ÓëÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÅäºÏ¿ª·¢²¢ÌṩSasaeru¡ª¡ªÒ»¿îͨ¹ý¼Ç¼³Õ´ôÖ¢»¼ÕßµÄÈÕ³£Éú»î»î¶¯£¨ADL£©£¬×ÊÖú´Ù½ø³Õ´ôÖ¢»¼Õß¡¢Ò½ÉúºÍ»¤ÀíÈËÔ±Ö®¼äÏàͬµÄÓ¦Ó÷¨Ê½¡£Theoria Technologies½«Í¨¹ý¼ÓÇ¿ÓëÆäËü¹«Ë¾µÄºÏ×÷À´´Ù½øÊý×Ö·þÎñµÄÉú³¤¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖÂÁ¦ÓÚͨ¹ýÉú̬ϵͳµÄ½¨Á¢ºÍÉú³¤£¬´òÔìÒ»¸öÄÜÈóմôÖ¢»¼ÕߺÍÈÕ³£Éú»îÁìÓòµÄÈËÃÇÆ¾¾Ý×Ô¼ºµÄÒâÔ¸Éú»îµÄ³Õ´ôÖ¢°üÈÝÐÔÉç»á£¬´Ó¶ø·¢ÉúÉç»áÓ°Ïì¡£

 

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

ÈÕ±¾Ò©ÊºÍʳƷÎÀÉúÉóÒé»áÐÂÒ©µÚÒ»²¿»á¹ØÓÚÂØ¿¨Ä¹µÄÉóÒé½á¹û

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡Ðû²¼ÈÕ±¾ºñÉúÀͶ¯Ê¡Ò©ÊºÍʳƷÎÀÉúÉóÒé»áÐÂÒ©µÚÒ»²¿»áÁªºÏÉùÃ÷£¬½¨ÒéÅú×¼ÂØ¿¨Ä¹£¨²úÎïÃû³Æ£ºLeqembi 200 mg ¾²Âö×¢ÉäÓÃÒ©ºÍ Leqembi 500 mg ¾²Âö×¢ÉäÓÃÒ©£©µÄÉú²úºÍÏúÊÛÐí¿ÉÉêÇë¡£

 

ÁªºÏÉùÃ÷

ÈÕ±¾ºñÉúÀͶ¯Ê¡Ò©ÊºÍʳƷÎÀÉúÉóÒé»áÐÂÒ©µÚÒ»²¿»á½¨ÒéÅú×¼ÓÃÓÚÖÎÁÆÔçÆÚ°¢¶û´Äº£Ä¬²¡ÂØ¿¨Ä¹µÄÉú²úºÍÉÏÊÐÐí¿ÉÉêÇ룬ÕâÊÇÈÕ±¾ÔÚÖÎÁư¢¶û´Äº£Ä¬²¡·½ÃæÂõ³öµÄÖØÒªÒ»²½¡£ÎÒÃǶÔËùÓмÓÈëÂØ¿¨Ä¹ÁÙ´²ÊÔÑéµÄ»¼Õß¡¢»¤ÀíÈËÔ±ºÍÒ½»¤ÈËÔ±ÌåÏÖÖÔÐĵÄлл¡£Ò»µ©»ñµÃÅú×¼£¬ÎÒÃǽ«¾¡×î´óŬÁ¦Ìá¹©ÂØ¿¨Ä¹£¬ÔÚÈÕ±¾¸ÃÒ©ÊÇÊ׸öÖ¤Ã÷¿ÉÃ÷ÏÔ½µµÍ°¢¶û´Äº£Ä¬²¡µÄ½øÕ¹ËٶȲ¢¼õ»ºÈÏÖªºÍ¹¦Ð§Ë¥Í˵ÄÒ©Æ·£¬ÊÇÔçÆÚ°¢¶û´Äº£Ä¬²¡»¼ÕßµÄÒ»ÖÖеÄÖÎÁÆÑ¡Ôñ¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Á¬Ðø22ÄêÈëÑ¡¸»Ê±Éç»áÔðÈÎÖ¸Êý£¨FTSE4GOOD£©

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉ磨ÒÔϼò³Æ¡±À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¡±£©Ðû²¼£¬¹«Ë¾ÈëÑ¡2023Ä긻ʱÉç»áÔðÈÎÖ¸Êý¡£×Ô2002ÄêÊ×´ÎÈëÑ¡¸»Ê±Éç»áÔðÈÎÖ¸ÊýÒÔÀ´£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÒÑÁ¬Ðø22Äê±»ÄÉÈë¸ÃÖ¸ÊýϵÁС£

FTSE4goodÖ¸ÊýϵÁÐÓɸ»Ê±ÂÞËØ£¨FTSE Russell£©¿ª·¢£¬Ö¼ÔÚ´Ù½ø×ʱ¾¶ÔÇкÏESG£¨È«Çò»·¾³¡¢Éç»áºÍÖÎÀí£©³ß¶È¹«Ë¾µÄͶ×Ê¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÔÚ¡°¹«Ë¾ÖÎÀí¡±¡¢¡°·´ÃÓÀᱡ¢¡°Ë°ÊÕ͸Ã÷¶È¡±¡¢¡°À͹¤³ß¶È¡±ºÍ¡°¿Í»§ÔðÈΡ±µÈ·½Ãæ¾ù»ñµÃ½Ï¸ß·ÖÊý¡£½ØÖÁ2023Äê6Ô£¬È«ÇòÓÐ1,121¼Ò¹«Ë¾±»ÄÉÈëFTSE4GoodÏȽøÖ¸ÊýϵÁУ¬ÆäÖаüÂÞ250¼ÒÈÕ±¾¹«Ë¾¡£

½ØÖ¹ÖÁĿǰ£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾³ýÁ˱»ÁÐÈëÈ«ÇòESGͶ×ÊÖ¸Êý¡ª¡ªMSCI ESGÁìµ¼ÕßÖ¸ÊýÖ®Í⣬»¹ÁÐÈëÁË GPIF£¨Õþ¸®ÑøÀÏͶ×Ê»ù½ð£©½ÓÄɵÄÈÕ±¾¹ÉƱESGͶ×ÊÖ¸Êý£¬È磺FTSE Blossom Japan index¡¢FTSE Blossom Japan Sector Relative index¡¢MSCIÈÕ±¾ESG¾«Ñ¡Áìµ¼ÕßÖ¸Êý¡¢MSCI WIN£¨ÈÕ±¾¸³È¨Å®ÐÔÖ¸Êý£©ºÍS&P/JPX̼ЧÂÊÖ¸Êý¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÄÆóÒµÀíÄîÊǽ«»¼ÕßÀûÒæ¼°¹«ÖÚ½¡¿µ·ÅÔÚÊ×룬Âú×ãÆä¶àÑù»¯ÐèÇó£¬ÎªÌáÉýÆä¸£ìí×ö³öТ¾´¡£Í¬Ê±£¬Í¨¹ýÔÚESGµÄ׿ԽÌåÏÖºÍÔö¼Ó·Ç²ÆÕþ¼ÛÖµ£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«Á¬ÐøÌáÉýÆóÒµ¼ÛÖµ¡£

 

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«ÔÚ2023Äê°¢¶û´Äº£Ä¬²¡Ð­»á¹ú¼Ê»áÒ飨AAIC£©ÉÏչʾ°üÂÞÂØ¿¨Ä¹ºÍANTI-MTBR TAU¿¹ÌåE2814ÔÚÄÚµÄ×îа¢¶û´Äº£Ä¬²¡²úÎïÏߺÍÑо¿½øÕ¹

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉçÐû²¼£¬½«ÔÚ2023Äê°¢¶û´Äº£Ä¬²¡Ð­»á¹ú¼Ê»áÒ飨AAIC£©ÉÏչʾÆä°¢¶û´Äº£Ä¬²¡£¨AD£©²úÎïÏߺÍ×îÐÂÑо¿½á¹û£¬°üÂÞÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÓÃÓÚÖÎÁư¢¶û´Äº£Ä¬²¡£¨AD£©µÄÂØ¿¨Ä¹£¨LEQEMBI?£©£¬ÒÔ¼°¹«Ë¾ÕýÔÚÑо¿µÄANTI-MTBR TAU¿¹ÌåE2814¡£»áÒ齫ÓÚ2023Äê7ÔÂ16ÈÕÖÁ20ÈÕÔÚºÉÀ¼°¢Ä·Ë¹Ìص¤¾ÙÐС£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«ÔڸûáÉϽøÐÐ8¸ö¿ÚÍ·³ÂËߺÍ19¸öº£±¨Õ¹Ê¾¡£ÆäÖÐÁ½¸öÔÚAAICÉϵĿÚÍ·³ÂËß½«Í¬Ê±ÔÚ°¢¶û´Äº£Ä¬²¡³ÉÏñÁªºÏ»á£¨AIC£©ÉÏÒÔº£±¨ÐÎʽ½øÐÐչʾ£¬AIC½«ÓÚ7ÔÂ15ÈÕÓëAAICÔÚͬһËùÔÚ¾ÙÐлáÒé¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÃÀ¹ú¸±Ê×ϯÁÙ´²¹Ù¼æADºÍÄÔ½¡¿µÁÙ´²Ñо¿¸ß¼¶¸±×ܲÃMichael Irizarry²©Ê¿ÌåÏÖ£¬”ÔÚAAIC 2023ÉÏ£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«Õ¹Ê¾¿¹A¦ÂÔ­ÏËά¿¹ÌåÂØ¿¨Ä¹µÄ×îÐÂÊý¾Ý£¬¸Ã¿¹Ìå×î½üÔÚÃÀ¹ú»ñµÃ´«Í³Åú×¼£¬ÓÃÓÚAD»òÇá¶ÈADËùÖÂÈÏÖªÕϰ­£¨MCI£©»¼Õß¡£ÂØ¿¨Ä¹Ôڹ㷺µÄÈËȺÖнøÐÐÁËÑо¿£¬ÆäÖаüÂÞ²îÒìÖÖ×åºÍ×åÒáȺÌåÒÔ¼°»¼Óг£¼ûºÏ²¢Ö¢ºÍͬʱ·þÓÃÒ©ÎïµÄ»¼Õß¡£´ËÍ⣬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾»¹½«Õ¹Ê¾ANTI-MTBR TAU¿¹ÌåE2814µÄÖØÒªÐÂÊý¾Ý£¬¸Ã¿¹ÌåĿǰÕýÔÚ»ªÊ¢¶Ù´óѧʥ·Ò×˹·ÖУµÄÏÔÐÔÒÅ´«ÐÔ°¢¶û´Äº£Ä¬ÊÏÖ¢NTU½øÐÐII/IIIÆÚÁÙ´²ÊÔÑé¡£×÷ΪÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¶Ô͸Ã÷¶ÈµÄÔÊÐíÒÔ¼°ÎÒÃǵÄhhc£¨human health care£¬ÌåÌùÈËÀཡ¿µ£©ºÍ´´½¨Éú̬ϵͳµÄʹÃüÖеÄÒ»²¿ÃÅ£¬ÎÒÃǽ«Á¬ÐøÕ¹Ê¾ºÍÐû²¼ÓйØÎÒÃǵÄAD²úÎïÏߺÍÑо¿½øÕ¹·½ÃæµÄÊý¾ÝºÍÐÅÏ¢¡£¡°

 

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÔÚAAICÉϽ«·¢±íµÄÄÚÈÝÈçÏ£º

ÀûÀ´w66(ÖйúÇø)_À´Àû¹ú¼ÊÆì½¢

ÂØ¿¨Ä¹µÄÈ«Çò¿ª·¢ºÍ¼à¹ÜÌá½»ÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ö÷µ¼£¬¶ø²úÎïÔòÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍÆ¹ã¡£ÆäÖУ¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÓµÓÐ×îÖÕ¾ö²ßȨ¡£

±¾ÐÂΟåÌÖÂÛµÄÊÇÔÚÑÐÖÆ¼ÁµÄÑо¿ÓÃ;£¬ÎÞÒâת´ï¹ØÓÚÓÐЧÐÔ»òÄþ¾²ÐԵĽáÂÛ¡£²»±£Ö¤´ËÀàÑо¿ÓÃÖÆ¼Á½«ÀÖ³ÉÍê³ÉÁÙ´²¿ª·¢»ò»ñµÃÒ©Æ·¼à¹Ü²¿ÃŵÄÅú×¼¡£

 

ýÌåÁªÂ磺
Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120

Eisai Inc. (U.S.)
Libby Holman
+ 1-201-753-1945
Libby_Holman@Eisai.com

Eisai Europe, Ltd.
(UK, Europe, Australia, New Zealand and Russia)
EMEA Communications Department
+44 (0) 786 601 1272
EMEA-comms@eisai.net

ÃÀ¹úFDAÅú×¼LEQEMBI?£¨lecanemab-irmb£©ÓÃÓÚÖÎÁư¢¶û´Äº£Ä¬²¡

ÕâÊÇÊ׸öÒ²ÊÇΨһһ¸ö±»Åú×¼µÄÖÎÁÆÒªÁ죬֤Ã÷Æä¿ÉÒÔ½µµÍ³ÉÈ˰¢¶û´Äº£Ä¬²¡»¼Õߵļ²²¡½øÕ¹µÄËÙ¶È£¬²¢ÑÓ»ºÈÏÖªºÍ¹¦Ð§Ë¥ÍË¡£

ÃÀ¹úÒ½ÁƱ£ÏÕºÍÒ½ÁƲ¹Öú·þÎñÖÐÐÄ£¨CMS£©Ðû²¼À©´óLEQEMBIµÄÒ½ÁƱ£ÏÕ·¶Î§¡£

 

2023Äê7ÔÂ6ÈÕ–À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉçºÍ²³½¡¹«Ë¾½ñÌìÐû²¼£¬ÃÀ¹úʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨FDA£©ÒѾ­Åú×¼LEQEMBI?£¨lecanemab-irmb£©100 mg/mL×¢ÉäÒºµÄÔö²¹ÉúÎïÖÆ¼ÁÐí¿ÉÉêÇ루sBLA£©£¬Ê¹LEQEMBI³ÉΪÊ׸öÒ²ÊÇΨһһ¸ö±»Åú×¼µÄÖÎÁÆÒªÁ죬֤Ã÷Æä¿ÉÒÔ½µµÍ³ÉÈ˰¢¶û´Äº£Ä¬²¡£¨AD£©»¼Õߵļ²²¡½øÕ¹ËÙ¶È£¬ÑÓ»ºÈÏÖªºÍ¹¦Ð§Ë¥ÍË¡£ÔÚÃÀ¹úÒ½ÁƱ£ÏÕÊÜÒæÈ˵ϼÕßȺÌåÖУ¬LEQEMBIÖ¤Ã÷Á˶ÔÈÏÖªºÍ¹¦Ð§Ë¥Í˾ßÓÐÁÙ´²ÒâÒåµÄÑÓ»º£¬¸ÃÈËȺ°üÂÞ¶à¸öÖÖ×åºÍÃñ×壬Óг£¼ûºÏ²¢Ö¢µÄ»¼Õߣ¬ºÏ²¢Ò©ÎïÖÎÁƵϼÕߣ¬ÒÔ¼°ADÔ´ÐÔÇá¶ÈÈÏÖªÕϰ­£¨MCI£©»òÇá¶ÈAD»¼Õß¡£LEQEMBIµÄÖÎÁÆÓ¦¸ÃÓÃÓÚÇá¶ÈÈÏÖªÕϰ­»òÇá¶È³Õ´ô½×¶ÎµÄ»¼Õߣ¨Í³³ÆÎªÔçÆÚAD£©ÊÇÔÚÁÙ´²ÊÔÑéÖпªÊ¼ÖÎÁƵÄÈËȺ¡£

LEQEMBIµÄ´«Í³Åú×¼ÊÇ»ùÓÚÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÄ´óÐÍÈ«ÇòClarity ADÁÙ´²ÊÔÑéµÄIIIÆÚÊý¾Ý¡£ÔÚ¸ÃÊÔÑéÖУ¬LEQEMBIµ½´ïÁËÆäÖ÷ÒªÖÕµãºÍËùÓÐÒªº¦´ÎÒªÖÕµãµÄͳ¼ÆÑ§ÒâÒåÉϵĽá¹û£¬²¢Ö¤ÊµÁËLEQEMBIµÄÁÙ´²»ñÒæ¡£Ö÷ÒªÖÕµãÊÇÈ«ÇòÈÏÖªºÍ¹¦Ð§Á¿±í£¬¼´ÁÙ´²³Õ´ôÖ¢ÆÀ·Ö×Ü±í£¨CDR-SB£©¡£Óëο½å¼ÁÏà±È£¬LEQEMBIÖÎÁÆÔÚ18¸öÔÂʱ¼õÉÙÁËCDR-SBµÄÁÙ´²Ï½µ27%¡£´ËÍ⣬ÓÉAD¿´»¤Õ߯À¹ÀµÄ´ÎÒªÖյ㰢¶û´Äº£Ä¬²¡Ð­×÷Ñо¿×é-Çá¶ÈÈÏÖªÕϰ­-ÈÕ³£Éú»îÄÜÁ¦Á¿±íÆÀ·Ö£¨ADCS MCI-ADL£©ÏÔʾ³ö37%µÄÏÔÖøÍ³¼ÆÑ§»ñÒæ¡£ÕâºâÁ¿µÄÊÇ»¼Õß¶ÀÁ¢ÔË×÷µÄÄÜÁ¦£¬°üÂÞÄܹ»´©Ò¡¢Î¹Ê³ºÍ¼ÓÈëÉçÇø»î¶¯¡£Clarity ADÑо¿µÄÈ«²¿½á¹ûÔÚ2022Äê°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©»áÒéÉÏÐû²¼£¬²¢Í¬Ê±·¢±íÔÚ2022Äê11ÔÂ29ÈÕµÄͬÐÐÆÀÉóҽѧÔÓÖ¾¡¶ÐÂÓ¢¸ñÀ¼Ò½Ñ§ÔÓÖ¾¡·ÉÏ¡£

ÖØÒªµÄÊÇ£¬ÔÚFDA¶ÔLEQEMBIµÄ´«Í³Åú×¼Ö®ºó£¬CMSÈ·ÈÏLEQEMBIµÄÁýÕÖÃæ½«À©´ó£¬²¢Ðû²¼ÁËÓйØ×¢²á±í·½ÃæµÄ¸ü¶àϸ½Ú£¬°üÂÞÒ×ÓÚʹÓõÄÊý¾ÝÌá½»Á÷³Ì¡£ÏÖÔÚ£¬ÓÉCMSÍÆ¶¯µÄ×¢²á±í¿É¹©Ò½»¤ÈËÔ±ÏòCMSÌá½»ËùÐèµÄ»¼ÕßÊý¾Ý¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÜÐË·ÜÒ½ÁƱ£ÏÕ½«ÎªºÏÊʵϼÕßÖ§¸¶ÕâÒ»ÖØÒªÁÆ·¨£¬Õ⽫´Ù½øÃÀ¹ú¸ü¶àµÄÒ½ÁÆ»ú¹¹À´±¨ÏúºÍʹÓÃLEQEMBI¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾CEOÄÚÌÙÇç·òÌåÏÖ£º¡°½ñÌ죬FDAÔÚ´«Í³µÄÉóÅú;¾¶ÏÂÅú×¼ÁËLEQEMBI£¬Ê¹LEQEMBI³ÉΪÊ׸öÒ²ÊÇΨһһ¸ö±»Åú×¼µÄ¿¹µí·ÛÑù±äµÄ°¢¶û´Äº£Ä¬²¡ÖÎÁÆÒ©Î֤Ã÷Æä¿ÉÒÔ½µµÍÔçÆÚºÍÇá¶È³Õ´ô½×¶ÎµÄ¼²²¡½øÕ¹ËٶȺÍÑÓ»º¼²²¡ÈÏÖªÕϰ­½øÕ¹¡£×÷Ϊһ¼Ò»ùÓÚhhc£¨human health care£¬ÌåÌùÈËÀཡ¿µ£©ÀíÄî¡¢ÒÔÑз¢ÎªÖصãµÄ¹«Ë¾£¬ÎÒÃǺÜ×ÔºÀ£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÔÚ¹ýÈ¥40ÄêÀADÑо¿½á¹ûµÃµ½ÁËÈϿɣ¬²¢ÌṩӦ¼²²¡»¼Õß¡£°¢¶û´Äº£Ä¬²¡ÊÇÒ»ÖÖ½¥½øµÄ¡¢ÖÂÃüµÄ¼²²¡£¬²»½ö¶Ô»¼ÕßÓкܴóÓ°Ï죬¶øÇÒ¶ÔËûÃǵÄÇ×ÈË¡¢¿´»¤ÕߺÍÉç»áÒ²ÓÐÓ°Ïì¡£ÎÒÃǼÌÐøÅ¬Á¦Îª»¼ÕßµÞÔì¹ã·º¶ø¼òµ¥µÄLEQEMBIʹÓÃȨ£¬²¢Ö§³ÖÔÚ¼²²¡µÄÔçÆÚ½×¶Î½øÐÐÕï¶ÏºÍÖÎÁÆ¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«ÇÚ·ÜÊÂÇ飬ÏòÒ½ÉúÁ÷´«Äþ¾²ºÍÊʵ±µØÊ¹ÓÃLEQEMBIµÄ֪ʶ£¬Ê¹Æä¶ÔÔçÆÚAD»¼Õß¼°Æä¼ÒÊôµÄÀûÒæ×î´ó»¯¡£¡±

²³½¡×ܲüæCEO Christopher A. ViehbacherÌåÏÖ£¬¡°½ñÌì±êÖ¾×Ű¢¶û´Äº£Ä¬²¡µÄÖÎÁÆÈ¡µÃÁËÍ»ÆÆÐÔ½øÕ¹£¬ÎÒÃǺÜ×ÔºÀÄܹ»Õ¾ÔÚǰÁУ¬ÎªÕâÖÖÒÔǰ±»ÈÏΪÎÞ·¨ÖÎÁƵļ²²¡¿ª´´Ò»¸öеĽøÕ¹Ê±´ú¡£ÎÒÃÇÒªÏòÄÇЩΪѰÕÒÕâÖÖÎ޽⼲²¡µÄÖÎÁÆÒªÁì¶ø²»Ð¸Å¬Á¦µÄÈËÌåÏÖÖÔÐĵÄлл£¬Ã»ÓÐËûÃǾͲ»ÐÐÄÜÈ¡µÃÕâÒ»½øÕ¹¡£ÎÒÃÇÔÚǰ½øµÄÃÅ·ÉÏÓëÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¹«Ë¾Ò»ÆðÊÂÇ飬Ŀ±êÊÇʹÇкÏÌõ¼þµÄ»¼Õß¾¡¿ì¿ÉÒÔʹÓÃLEQEMBI¡£¡±

LEQEMBIÊÇÒ»ÖÖÈËÔ´»¯ÃâÒßÇòÂѰצÃ1£¨IgG1£©µ¥¿Ë¡¿¹Ì壬Õë¶Ô¾Û¼¯µÄ¿ÉÈÜÐÔ£¨Ô­ÏËά*£©ºÍ²»ÐÐÈÜÐÔÐÎʽµÄ¦Âµí·ÛÑùÂѰף¨A¦Â£©¡£ÖØÒªµÄÊÇ£¬LEQEMBIÕë¶Ô²¢Çå³ýÁ¬Ðø»ýÀÛµÄ×î¾ßÉñ¾­¶¾ÐÔµÄA¦ÂÐÎʽ£¬²¢Çå³ýÏÖÓа߿飬ÒÔÖÎÁÆÕâÖÖ½¥½øµÄÂýÐÔ¼²²¡¡£2023Äê6Ô£¬ÃÀ¹úFDAÖÜΧºÍÖÐÊàÉñ¾­ÏµÍ³Ò©ÎPCNS£©×ÉѯίԱ»áȫƱͨ¹ý£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÄClarity ADÁÙ´²ÊÔÑéÊý¾Ý֤ʵÁËLEQEMBI¶ÔÖÎÁÆADµÄÁÙ´²»ñÒæ¡£Î¯Ô±»á³ÉÔ±»¹È·ÈÏÁËLEQEMBIµÄÕûÌå·çÏÕ-»ñÒæ¡£2023Äê1ÔÂ6ÈÕ£¬LEQEMBIÔÚ¼ÓËÙÉóÅú;¾¶Ï»ñµÃFDAÅú×¼¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÒѾ­¿ª·¢²¢²¿ÊðUnderstanding ARIA?£¬ÕâÊÇÒ»¸ö¶à·½ÃæµÄ½ÌÓý¼Æ»®£¬Ö¼ÔÚ½øÒ»²½´Ù½øADÒ½Áƽç¶Ôµí·ÛÑùÂѰ×Ïà¹Ø³ÉÏñÒì³££¨ARIA£©µÄʵ¼Ê¹ÜÀíºÍ¼à²âµÄÀí½â¡£Í¨¹ýÓëҽѧӰÏñÁìÓòµÄר¼ÒÒÔ¼°Ö÷ÒªµÄרҵЭ»áºÏ×÷£¬Understanding ARIA?ÌṩµÄ×ÊÔ´ºÍ¼Æ»®£¬°üÂÞͬÐнÌÓý¡¢¸öÈ˺ÍÍÅÌå½ÌÓý¿Î³ÌÒÔ¼°ÀúÊ·°¸ÀýÑо¿µÄÖ÷Ìâר¼ÒÆÀ¹ÀµÈÄÚÈÝ¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖÂÁ¦ÓÚÈ·±£ºÏÊʵϼÕßÄܹ»»ñµÃLEQEMBI£¬²¢½¨Á¢ÁËÒ»¸ö»¼ÕßÔ®Öú¼Æ»®£¬ÎªÇкϾ­¼ÃÐèÇóºÍÆäËû¼Æ»®³ß¶ÈµÄÎÞ±£Ïպͱ£ÏÕ²»×ãµÄ»¼Õߣ¨°üÂÞÒ½ÁƱ£ÏÕÊÜÒæÈË£©Ãâ·ÑÌṩLEQEMBI¡£´ËÍ⣬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾»¹Í¨¹ýLEQEMBI»¼ÕßÁ캽ԱÏîÄ¿Ìṩ»¼ÕßÖ§³Ö£¬ÒÔ¸ÄÉÆ»ñȡ;¾¶£¬ËûÃǽ«ÌṩÓйػñÈ¡LEQEMBIµÄÐÅÏ¢£¬×ÊÖú»¼Õß¼°Æä¼ÒÊôÁ˽âËûÃǵı£ÏÕ·¶Î§ºÍÑ¡Ôñ£¬²¢ÎªÇкÏÌõ¼þµÄ»¼ÕßÈ·¶¨²ÆÕþÖ§³Ö¼Æ»®¡£ÔÚÃÀ¹ú£¬ÈËÃÇ¿ÉÒÔͨ¹ý·ÃÎÊLEQEMBI.com¡¢ÔÚ¶«²¿Ê±¼äÖÜÒ»ÖÁÖÜÎåÉÏÎç8µãÖÁÍíÉÏ8µã²¦´ò1-833-4 LEQEMBI£¨1-833-453-7362£©»ò½«×¢²á±í´«ÕæÖÁ1-833-770-7017£¬Á˽â¸ü¶à¹ØÓÚÕâЩ·þÎñ¡£

LEQEMBIµÄÈ«Çò¿ª·¢ºÍ¼à¹ÜÌá½»ÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ö÷µ¼£¬¶ø²úÎïÔòÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍÆ¹ã¡£ÆäÖУ¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÓµÓÐ×îÖÕ¾ö²ßȨ¡£

 

ýÌåÁªÂ磺
Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120

Biogen Inc.
Jack Cox
+ 1 781-464-3260
public.affairs@biogen.com

Eisai Inc. (U.S.)
Libby Holman
+ 1-201-753-1945
Libby_Holman@eisai.com

Eisai Europe, Ltd.
(UK, Europe, Australia, New Zealand and Russia)
EMEA Communications Department
+44 (0) 786 601 1272
EMEA-comms@eisai.net

Investor Contacts:
Eisai Co., Ltd.
Investor Relations Department
TEL: +81 (0) 3-3817-5122

Biogen Inc.
Chuck Triano
+ 1-781-464-2442
IR@biogen.com

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¡¢¸Ç´Ä·çÏÕͶ×Ê¡¢Ó¢¹ú½¡¿µÊý¾ÝÑо¿¹«Ë¾¡¢LIFEARCºÍ°®¶¡±¤´óѧÐû²¼È«ÐÂNEURIIÑо¿ºÏ×÷ÒÔ¿ª·¢³Õ´ôÖ¢µÄÊý×Ö½â¾ö·½°¸

  • еÄÑо¿ºÏ×÷»ã¼¯ÁËÔÚÉñ¾­¿ÆÑ§·½ÃæÓйØÖÎÁÆ¡¢¼¼Êõ¡¢½¡¿µÊý¾Ý¡¢¼¼ÊõÉÌÒµ»¯ºÍ¸ß¼¶·ÖÎö/Êý¾Ý¿ÆÑ§µÈÊÀ½çÁìÏÈ»ú¹¹µÄ¼¯Ìåר³¤¡£
  • Á½ÄêµÄÊԵ㽫Ϊ¿ÆÑ§Ô­ÐÍת»¯ÎªÖ¤Ã÷¶ÔÏÖʵÊÀ½çÓÐÓ°ÏìµÄʵ¼Ê½â¾ö·½°¸ÌṩÁËÒ»¸öÆô¶¯Æ½Ì¨¡£
  • NEURiiµÄºÏ×÷Êǽ¨Á¢ÔÚÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Éñ¾­²¡Ñ§ÁìÓò´´ÐÂÖÎÁÆ·½Ã渻ºñ¾­ÑéÖ®ÉÏ£¬²¢½«Á¬Ðø¶ÔÈ«ÇòÊý×Ö½¡¿µÉú̬ϵͳ·¢ÉúТ¾´¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¡¢¸Ç´Ä·çÏÕͶ×Ê¡¢Ó¢¹ú½¡¿µÊý¾ÝÑо¿¹«Ë¾£¨HDR UK£©¡¢LifeArcºÍ°®¶¡±¤´óѧÐû²¼ÁËÒ»ÏîΪÆÚÁ½ÄêµÄкÏ×÷Ñо¿Ð­Òé¡£ÕâÏîºÏ×÷±»ÃüÃûΪNEURii£¬ÊÇÒ»ÖÖ¼¯¸÷¼ÒËù³¤Ç¿´óÇÒÆæÌصÄÏÈ·æºÏ×÷¹ØÏµ£¬½«ÔÚÖÎÁÆ¡¢¼¼Êõ¿ª·¢ºÍÉÌÒµ»¯¡¢½¡¿µÊý¾Ý¹ÜÀíºÍÏȽø·ÖÎö/Êý¾Ý¿ÆÑ§·½ÃæÔ¤²â¡¢±£»¤ºÍ´Ù½ø´óÄÔ½¡¿µ¡£

NEURii½«°Ñ×î³õµÄÊÂÇéÖØµã·ÅÔÚ¿ª·¢Êý¾ÝºÍÊý×Ö½â¾ö·½°¸ÉÏ£¬ÒÔÔö²¹ÒÑÅú×¼µÄ»¼ÕßÖÎÁÆ·½°¸£¬²¢½â¾öÓë³Õ´ôÖ¢Ïà¹Ø¼²²¡µÄÔ¤²â¡¢Ô¤·À¡¢¹ÜÀíºÍÖÎÁÆÎÊÌâ¡£

ÕâÏ´´ÐԵĺÏ×÷½«ÀûÓøßÖÊÁ¿µÄ¸öÈËÊý¾Ý¡¢È˹¤ÖÇÄÜ£¨AI£©ºÍ»úÆ÷ѧϰ£¨ML£©£¬Í¨¹ý¿ªÆðÔ´×Ը߶ÈÈϿɵÄÓ¢¹úѧÊõÖÐÐĵĿª¶ËÊÔµãÏîÄ¿£¬ÌṩÒÔ²¡ÈËΪÖÐÐĵÄÊý×Ö½¡¿µ½â¾ö·½°¸¡£ÕâЩÏîÄ¿±»Ñ¡ÖеÄÒÀ¾ÝÊÇËüÃÇÔÚά»¤Êý¾ÝÄþ¾²ºÍ¹«ÖÚÐÅÈεÄͬʱ£¬ÓпÉÄܶԻ¼ÕßµÄÉú»î·¢ÉúÓÐÒâÒåµÄÓ°Ï졣ͨ¹ý½«¿ÉÒÔÔÚÕæÊµÊÀ½çÁÙ´²ºÍ·ÇÁÙ´²»·¾³ÖзÇÇÖÈëÐԵػñµÃµÄÖÖÖÖÊý×ÖÉúÎï±êÖ¾ÎÀýÈ磬¶Ô»°ÖеÄÓïÒô£©ÓëÓ¢¹ú»ýÀ۵ĸßÖÊÁ¿ºÍ¸»ºñµÄÒ½ÁÆÊý¾ÝÏà½áºÏ£¬²¢Í¨¹ý¶¨ÖƵÄÈ˹¤ÖÇÄÜËã·¨½øÐзÖÎö£¬NEURii½«µÞÔ촴еÄÊý×Ö½â¾ö·½°¸¡£ÕâЩ½â¾ö·½°¸½«±»²¿ÊðÔÚ³Õ´ôÖ¢»¼Õߵļì²â¡¢¼à²âºÍÖÎÁÆÖУ¬ÒÔ¸ÄÉÆËûÃǵÄÉú»î£¬²¢×î´óÏ޶ȵؼõÉÙ¼²²¡¸ºµ£¶ÔÆäÕÕ¹ËÕߺͼÒÍ¥µÄÓ°Ïì¡£

ÕâÏîΪÆÚÁ½ÄêµÄ¿ª¶ËÊԵ㽨Á¢ÁËÒ»¸öÒ»Á÷µÄÆô¶¯Æ½Ì¨£¬¸Ãƽ̨ÒÔ´´ÐµÄÉÌҵģʽºÍ¿ÉÀ©Õ¹µÄÔ­ÐÍΪ»ù´¡£¬½«¶Ô¿ÆÑ§Ô­ÐͽøÐÐת»¯£¬¼ÓÇ¿ºÍ¸ÄÉÆ¹«¹²ÎÀÉú·½ÃæµÄ´ëÊ©£¬Õ¹Ê¾Æä¶ÔÕæÊµÊÀ½çµÄÓ°Ï졣ƾ¾ÝÉèÏ룬NEURiiºÏ×÷»ï°é½«Ì½Ë÷½øÒ»²½Éú³¤»ú»á£¬À©´ó¸Ã¼Æ»®µÄ¹æÄ££¬½«ÔÚÊÀ½ç¸÷µØ¿ª·¢Êý×Ö½¡¿µ½â¾ö·½°¸¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Éî¶ÈÈËÀàÉúÎïѧѧϰ£¨DHBL£©×é֯ѧÊõºÍ¹¤ÒµÁªÃ˹ÙÔ±Teiji Kimura²©Ê¿ÆÀÂÛµÀ£¬”³Õ´ôÖ¢ÊÇÀÏÁ仯Éç»áµÄÖ÷ÒªÉç»áºÍÒ½ÁÆÎÊÌâÖ®Ò»£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÄʹÃüÊÇΪ½â¾öÕâЩÎÊÌâ×ö³öТ¾´¡£ÎÒÃǵÄÄ¿±êÊǵÞÔìеÄÊý×Ö½â¾ö·½°¸£¬Í¨¹ý½áºÏÓ¢¹úÔÚÕâÒ»ÁìÓòµÄÁìÏÈְλÒÔ¼°ÎÒÃÇÔÚ³Õ´ôÖ¢ÁìÓò²»Í£½¨Á¢µÄ´´ÐÂÁÆ·¨µÄ¾­ÑéºÍ¼Ç¼£¬Í¬Ê±¼á³ÖÎÒÃǵÄhhcÀíÄhuman health care£¬ÌåÌùÈËÀཡ¿µ£©£¬¼´Ê×ÏÈ¿¼ÂDz¡»¼ºÍÈÕ³£Éú»îÁìÓòµÄÈË£¬Îª½â¾ö³Õ´ôÖ¢µÄÌôÕ½×ö³öТ¾´¡£”

¾ÝÔ¤¼Æ£¬Ä¿Ç°ÊÀ½çÉÏÓÐÁè¼Ý5500ÍòÈË»¼ÓгմôÖ¢¡£ÔÚÓ¢¹úÓнü100ÍòÈË£¬¶øÇÒÕâ¸öÊý×ÖÔ¤¼Æ»áѸËÙÔö³¤¡£³ýÁ˶Ի¼ÕߺÍÕÕ¹ËËûÃǵÄÈ˵ÄÉú»î·¢ÉúÖØ´óÓ°Ï죬ÕâЩÇé¿ö¶Ô½¡¿µºÍÉç»á»¤ÀíϵͳÔì³ÉÁ˾޴óѹÁ¦¡£ÌṩÊý¾ÝÇý¶¯µÄ½â¾ö·½°¸£¬Ôö²¹ÏÖÓеÄÖÎÁÆÒªÁ죬¿ÉÒÔ×ÊÖú¸ÄÉÆÔçÆÚ¼ì²âºÍÕï¶Ï£¬»ùÓÚÖ¤¾ÝµÄÖÎÁƾö²ß£¬¼à²â¼²²¡µÄÉú³¤ºÍά³ÖÉú»îÖÊÁ¿¡£

¸Ç´Ä¸Ç´Ä·çÏÕͶ×ʽ¡¿µÓëÉúÃü¿ÆÑ§Ö´ÐÐ×ܲÃNiranjan Bose²©Ê¿ÌåÏÖ£¬”ÎÒ¶ÔNEURiiºÏ×÷³äÂúÆÚ´ý£¬È˹¤ÖÇÄÜºÍÆäËüÏȽø¼¼Êõ¿ªÊ¼ÔÚҽѧÑо¿Öз¢»ÓÇ¿´óµÄ×÷Ó㬰ÑÕâЩ¹¤¾ßÓ¦ÓÃÓÚÕï¶ÏÑо¿ºÍÒ©Îï·¢ÏÖ£¬²¢´Ù½øÍ»ÆÆ£¬¸ÄÉÆÊý°ÙÍò³Õ´ôÖ¢ºÍ³Õ´ôÖ¢Ïà¹Ø¼²²¡»¼ÕßµÄÉú»î¡£”

LifeArc¹«Ë¾MNDת»¯ÌôÕ½ÏîÄ¿ÂôÁ¦ÈËPaul WrightÌåÏÖ£¬”È·¶¨Ô¤·À³Õ´ôÖ¢ºÍÉñ¾­ÍËÐÐÐÔ¼²²¡µÄÒªÁìÊÇÎÒÃǼÛÖµÊý°ÙÍòÓ¢°÷µÄÉñ¾­ÍËÐÐÐÔÏîÄ¿µÄÒ»¸öÒªº¦²¿ÃÅ¡£ÕâÏîºÏ×÷ÊÇÎÒÃǼÓÈëµÄÐí¶àд´ÐÂÏîĿ֮һ£¬Ä¿µÄÊǸÄÉÆ³Õ´ôÖ¢µÄÕï¶Ï£¬ÊÇÏòÔ¤²âÄÇЩ¿ÉÄÜÉú³¤³ÉÕâÖÖ¼²²¡µÄÈËÂõ³öµÄ»ý¼«Ò»²½”¡£

Ó¢¹úÊÇÊý×Ö¼¼ÊõͶ×ʺÍÑо¿µÄÁìµ¼Õߣ¬Éæ¼°»ùÒò×éѧ¡¢½¡¿µÊý¾Ý¿ÆÑ§¡¢È˹¤ÖÇÄܺÍMLµÈÁìÓò£¬ÓµÓи»ºñ¶àÑùµÄ½¡¿µÏà¹ØÊý¾Ý¡£NEURiiµÄģʽ½«Äܹ»Ê¶±ðÇ°ÑØÊý¾ÝºÍÊý×Ö¿ÆÑ§£¬Ö¸µ¼ÓÅÐãµÄ¿ÆÑ§¼Ò£¬²¢½«½¡¿µÔ­ÐÍת»¯ÎªÊµÓúͿɻñµÃµÄ²úÎͨ¹ý»ã¼¯NEURiiºÏ×÷ÕßµÄרҵ֪ʶºÍÄÜÁ¦£¬Ï£ÍûÕâÖÖÐÂÓ±µÄÒªÁ콫ΪеÄÀå¸ïÐÔÊý×Ö²úÎïÌṩһ¸öÁîÈËÐË·ÜµÄÆô¶¯Æ½Ì¨£¬ÒÔ´Ù½ø½â¾ö³Õ´ôÖ¢ºÍÉñ¾­ÍËÐÐÐÔ¼²²¡µÄÁ¬ÐøÌôÕ½¡£

Ó¢¹úHDRÖ÷ÈÎAndrew Morris½ÌÊÚÌåÏÖ£¬ “Ó¢¹úÓнüÒ»°ÙÍòÈË»¼ÓгմôÖ¢¡£Õâ¸öÐµĹ«Ë½ºÏÓªÏîĿּÔÚͨ¹ýÔÚÄþ¾²»·¾³ÏÂÖµµÃÐÅÀµµØÊ¹ÓÃÄäÃû½¡¿µÊý¾ÝµÄ´óÐÍÊý¾Ý¼¯£¬¸üÉîÈëµØÁ˽âÕâÖÖ¼²²¡¡£ÎÒÃǽ«ÍƽøÒ»ÏµÁеÄÊÔµãÏîÄ¿£¬²¢Ó빫ÖÚ½Ó´¥¡£ÎÒÃǵÄÄ¿±êÊÇÉú²úеÄÊý¾ÝÇý¶¯µÄ²úÎʹ»¼Õß¼°Æä¼ÒÊôÔÚ¼ì²â³Õ´ôÖ¢¡¢Ô¤²âÆä½øÕ¹ºÍ¸üºÃµØ¹ÜÀí¼²²¡·½ÃæÊÜÒæ”¡£

NEURiiºÏ×÷µÄ½á¹û½«Ã¿¼¾¶ÈÔÚÄÚ²¿ÃÅÏí£¬²¢ÔÚÊÊÆäʱºò¶ÔÍâÐû²¼¡£

 

ýÌåÁªÂç:
Eisai Co., Ltd.
Public Relations Department
+81-(0)3-3817-5120

Eisai Europe, Ltd.
Bily Kuo
Director, Communications EMEA
emea-comms@eisai.net
+44 (0) 7739 600 678

For queries relating to any of the signing partners: UoE, Gates Ventures, LifeArc and HDRUK
University of Edinburgh/Edinburgh Innovations
Megan Welford
Communications Manager
Megan.welford@ei.ed.ac.uk
+44 07721 120217

ÌÚѶ½¡¿µÓëÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúÉսÂÔºÏ×÷ ЭÁ¦´òÔìÊý×Ö»¯´´ÐÂз¶Ê½

6ÔÂ26ÈÕ£¬ÌÚѶ½¡¿µÓëÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúÇ©ÊðÕ½ÂÔºÏ×÷ЭÒ顣˫·½½«ÒÔÌÚѶ½¡¿µÒ½Ò©ÐÐÒµSaaS½â¾ö·½°¸¡ª¡ªNGES (Next Generation Engagement Suite)ÏÂÒ»Õ¾Ò½Éú»¥¶¯¹ÜÀíÆ½Ì¨Îªµ××ù£¬Í¨¹ý½«ÌÚѶÁ¬½ÓÓÅÊÆºÍÊý×Ö¼¼Êõ£¬ÓëÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öйú¿Í»§¹ÜÀí¡¢¶àÇþµÀÓªÏúºÍ»áÒé»î¶¯¹ÜÀíµÈºËÐij¡¾°ÐèÇóÉî¶È½áºÏ£¬×ÊÖúÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúÂòͨȫÓò³¡¾°£¬´®Áª¡°Ó¦Óùµº¡±£¬ÊµÏÖÏßÉÏÏßÏÂÒ»Ì廯µÄѧÊõÏàͬз¶Ê½£¬ÒÔ¹ÜÀíÉý¼¶ºÍģʽ¸ïÐÂÁ¬ÐøÉî¸ûÖйúÊг¡£¬ÊµÏÖ¸ßÖÊÁ¿Éú³¤¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾È«Çò¸ß¼¶¸±×ܲá¢À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öйú×ܲ÷ëÑÞ»Ô£¬ÌÚѶ½¡¿µ¸±×ܲá¢ÒµÎñÂôÁ¦ÈËÎâÎĴÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúÉñ¾­¿ÆÑ§ÁìÓòÊÂÒµ±¾²¿×ܾ­ÀíÖÜÑó£¬ÌÚѶ½¡¿µ¸±×ܲÃÕÅÓå·Ö±ð´ú±íË«·½³öϯսÂÔºÏ×÷ǩԼÒÇʽ¡£

ÀûÀ´w66(ÖйúÇø)_À´Àû¹ú¼ÊÆì½¢ÏÖ³¡Ç©Ô¼ÒÇʽÕÕÆ¬£¬×óÆð£ºÖÜÑó¡¢·ëÑÞ»Ô¡¢ÎâÎÄ´ï¡¢ÕÅÓå

Ëæ×ÅÒ½Ò©Êý×Ö»¯Ë®Æ½µÄÖð²½ÌáÉý£¬Ò½Ò©ÐÐÒµÊý×Ö»¯µÄÉú³¤Õý×ßÏòÔ½·¢ÖÇÄÜ»¯ºÍ¾«Ï¸»¯¡£ÖÖÖÖÊý×Ö¼¼ÊõµÄÓ¦Ó㬽«ÎªÒ½Ò©ÆóÒµ½µ±¾ÔöЧ·¢»ÓÔ½À´Ô½ÖØÒªµÄ×÷Óá£×÷Ϊ¿ç¹úÖÆÒ©Ñз¢ÐÍÆóÒµÔÚ»ªÖ÷Ì壬´Ë´ÎÒýÈëÌÚѶ½¡¿µÖÇ»ÛÒ½Ò©NGESƽ̨ÊÇÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúÓëÌÚѶ»áÒéºÏ×÷µÄÈ«ÃæÉý¼¶£¬Í¨¹ýÓëרҵҽÉúѧÊõ»¯Ïàͬȫ³¡¾°Ò»Õ¾Ê½Âòͨ£¬ÒÔÐÅϢЭͬ¡¢Êý¾Ý»¥ÁªÊµÏÖ¾«×¼»¯Ñ§Êõ½ÌÓý£¬ÖúÁ¦À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúÉñ¾­¿ÆÑ§¡¢Ö×Áö¿ÆÑ§ºÍÏû»¯¸Î²¡µÈ¶à¸öÁìÓò´´Ð²úÎïÊг¡¿ªÍغͻ¼Õ߿ɼ°ÐÔ¡£

NGESÊÇÌÚѶ½¡¿µÃæÏòÒ½Ò©ÐÐÒµµÄSaaS½â¾ö·½°¸£¬ÒÔ΢ÐÅС·¨Ê½ÎªÔØÌ壬ÒÔCRM£¨Ò»Õ¾Ê½¿Í»§Ôì·Ã£©¡¢Events£¨ÏßÉÏÏßÏ»áÒé¹ÜÀí£©¡¢MCM(¶àÇþµÀÄÚÈÝÓªÏú)Èý´ó³¡¾°ÎªºËÐÄ£¬½«Ò½Éú»¥¶¯È«Á÷³Ì»·½Ú²ð·Öϸ»¯£¬»ùÓÚ΢ÐÅС·¨Ê½ºÍÆäËûÊýÖǹ¤¾ß£¬´ÓÒ½Éú»¥¶¯³¡¾°Ò»Õ¾Ê½Âòͨ¡¢´¥´ïÓû§Í¬Ê±½øÐÐË«Ïò»¥¶¯¡¢ÌṩÖÇÄÜÐÐΪ½¨ÒéµÈ·½ÃæÖúÁ¦Ò½Ò©ÆóÒµÉî¶ÈÁ¬½ÓÒ½Éú£¬ÈÃѧÊõ»¯ÏàͬԽ·¢±ã½Ý¡¢Ë³³©¡¢¸ßЧ¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾È«Çò¸ß¼¶¸±×ܲá¢À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öйú×ܲ÷ëÑÞ»ÔŮʿÌåÏÖ£º¡°À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúʼÖÕ³ÐÏ®hhc (human health care£¬ÌåÌùÈËÀཡ¿µ)ÆóÒµÀíÄ¼ùÐÐhhceco£¨hhc ecosystem£©Éú³¤Ä£Ê½¡£´Ë´ÎÓëÌÚѶ½¡¿µÉºÏ×÷ÊÇÖйúÇø¡®Ð²úÎï¡¢ÐÂÇþµÀ¡¢ÐÂÆ½Ì¨¡¢ÐÂÒµÎñ¡¯ËÄÐÂÕ½ÂÔµÄÖØÒªÒ»»·£¬Ë«·½½«³äʵ·¢»Ó¸÷×ÔÔÚÇ°ÑØÁÆ·¨ºÍÊý×Ö¼¼ÊõÁìÓòµÄÁìÏÈÓÅÊÆ£¬ÅäºÏ̽Ë÷ÃæÏòδÀ´µÄרҵ»¯Ñ§ÊõÏàͬ´´ÐÂģʽ£¬½¨Á¢¸ßЧÐÅϢͨ±¨ÇÒ¿ÉÁ¬ÐøµÄÉÌҵѭ»·£¬²»Í£º»ÊµÆóÒµÐÅÏ¢»¯Éú³¤µÄ»ù´¡ÉèÊ©½¨Éè¡£¡±

ÌÚѶ½¡¿µ¸±×ܲÃÎâÎÄ´ïÌåÏÖ£º¡°ÔÚÊг¡»·¾³¼ÓËÙÑݱäµÄÅä¾°Ï£¬Ò½Ò©ÐÐÒµÊý×Ö»¯×ªÐÍÕý°´Ï¡®¼ÓËÙ¼ü¡¯£¬Ï£Íûͨ¹ýNGESһվʽ»¥¶¯Æ½Ì¨£¬×ÊÖúÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúÖØ¹¹ÓëÒ½ÉúµÄ»¥¶¯´¥µãºÍ¶Ô»°Ä£Ê½£¬Çý¶¯Ñ§Êõ»¯Ïàͬ¶àÇþµÀÏßÉÏÑÓÉìµÄͬʱ£¬ÒÔÐÅÏ¢¹²Ïí¸¨ÖúÖÇÄÜ¡¢Ãô½Ý¾ö²ß£¬ÎªÒ½Ò©ÆóÒµÉý¼¶×ªÐÍ´ò¿ª¸ü¶àÐÂ˼·ºÍÄÜЧ¿Õ¼ä¡£¡±

Ŀǰ£¬ÔÚÒ½Ò©Ñз¢¡¢ÖÆÔì¡¢ÓªÏú¡¢·þÎñµÈ¶à¸öÉú²ú¾­Óª³¡¾°ÖУ¬³ýNGESѧÊõ»¯Ïàͬƽ̨Í⣬ÌÚѶ½¡¿µÒÑÐγɰüÂÞÈ˹¤ÖÇÄÜÒ©Îï·¢ÏÖ¡¢½¡¿µÒ©Ïä·þÎñ¡¢ÔÆÄþ¾²µ××ùµÈÊý×Ö»¯ÄÜÁ¦È«Í¼Æ×£¬ÒÔÊý×ÖºËÐıäÁ¿ÊµÏÖÑз¢Ð§ÂʵÄÌáÉýºÍÒ½Ò©·þÎñµÄ¸ïС£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÄ¡°NOUKNOW?¡±½«¼ÌÐø×÷Ϊ¶«¾©Îľ©Çø2023ÄêÀÏÄê³Õ´ôÖ¢¼ì²éÏîÄ¿µÄÒ»²¿Ãű»ÓÃÓÚ´óÄÔ½¡¿µÆÀ¹À

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉçÐû²¼£¬×÷Ϊ¶«¾©Îľ©Çø¿ªÕ¹µÄ2023²ÆÄê³Õ´ôÖ¢¼ì²éÏîÄ¿µÄÒ»²¿ÃÅ£¬½«¼ÌÐøÍÆ¹ãÀûÓÃÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÈÏÖª¹¦Ð§×ÔÎÒÆÀ¹ÀµÄÊý×Ö¹¤¾ß “NouKNOW?”½øÐдóÄÔ½¡¿µ¼ì²é¡£

¸ÃÏîĿּÔÚÃãÀøÔ¼Äª12,300Ãû55ÖÁ75ËêµÄÎľ©Çø¾ÓÃñ£¬ÒÔÿ5ÄêΪһ¸öÀï³Ì±®£¬Ê¹Óà “NouKNOW “½øÐдóÄÔ½¡¿µ¼ì²é¡£½ÓÊÜÆÀ¹ÀµÄÈË¿ÉÒÔÖ±½Ó´ÓÏÖ³¡Ò½ÉúÄÇÀïµÃµ½»ùÓÚÆÀ¹À½á¹ûµÄÒ½Áƽ¨Ò顣ƾ¾ÝÆÀ¹À½á¹û£¬¿ÉÒÔתÕïµ½Ò½ÁÆ»ú¹¹½øÐÐ×Éѯ£¬²¢µÃµ½ÉÏÃÅ»¤Ê¿µÄ×ÊÖú¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍÎľ©ÇøÓÚ2015Äê6ÔÂÇ©ÊðÁË¡°ÉçÇø½¨Éè»ï°é¹ØÏµÐ­Òé¡ªÍÆ½ø³Õ´ôÖ¢»¼Õß¼°Æä¼ÒÈ˵ĵ±µØ³Õ´ôÖ¢Ö§³Ö³«Ò顱£¬ÅäºÏÍÆ¶¯ÖÖÖÖÊÂÇ飬°üÂÞ³Õ´ôÖ¢¿§·È¹Ý¡¢£¬ÑûÇëÒ½ÉúΪ¾ÓÃñÊڿΣ¬²¢ÔËÓªÒ»¸ö¾ÓÃñ´ú¼Ê½»Á÷ÉçÇøÖÐÐÄ¡£

×÷ΪÎľ©ÊеÄÓÅÏÈÕþ²ß£¬³Õ´ôÖ¢¼ì²éÏîÄ¿×Ô2021²ÆÄ꿪ʼʵʩ£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ò»Ö±ÎªÆäÌṩ “NouKNOW “¼ì²éºÍÔËÓªÖ§³Ö¡£ÔÚ2022²ÆÕþÄê¶È£¬ÒýÈëÁËÀÖ³ÉÖ§¸¶£¨PFS£©ºÏͬ£¬Ö¼ÔÚ½øÒ»²½¼ÓÇ¿¶Ô³Õ´ôÖ¢µÄÈÏʶºÍÔçÆÚÖ§³Ö£¬²¢È·¶¨ÁËÏà¹Ø½á¹ûÖ¸±ê¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÊÜ´ËÏîĿίÍУ¬Í¨¹ý “NouKNOW “ÊÔÑé»î¶¯ºÍÃæÏò¾ÓÃñµÄÄÔ½¡¿µ¹ûÈ»½²×ùµÈÍÆ¹ã´ëÊ©£¬ÊµÏÖÁ½Ïî½á¹ûÖ¸±ê¡£

  • ½á¹ûÖ¸±ê1£ºÔö¼ÓÔÚ¼ÒÖÐʹÓà “NouKNOW “½øÐеĴóÄÔ½¡¿µ¼ì²éµÈ¡£
  • ½á¹ûÖ¸±ê2£ºÌá¸ßÉú»î·½Ê½¸ÄÉÆ¼Æ»®µÄ¼ÓÈë¶È¡£

ÔÚ2022²ÆÕþÄê¶È£¬ÓÐ430È˼ÓÈëÁËÏÖ³¡¼ì²é£¨Ê¹Óà “NouKNOW “¼ì²âºÍҽѧ·Ã̸£©£¬ÆäÖÐÔ¼10%µÄÈ˱»½¨Òéµ½Ò½ÁÆ»ú¹¹¾ÍÕï¡£ÔÚ2023²ÆÕþÄê¶È£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«¼ÌÐøÌá¸ß¾ÓÃñ¶Ô´óÄÔ½¡¿µµÄÈÏʶ£¬ÎªÔçÆÚ·¢ÏÖºÍÖ§³Ö³Õ´ôÖ¢×ö³öТ¾´¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÒÑÓëÈÕ±¾¸÷µØ·½Õþ¸®¡¢Ò½ÁÆÐ­»áºÍÆäËû×é֯ǩ¶©ÁËÇøÓòºÏ×÷ЭÒ飬²¢ÕýÔÚÍÆ¶¯ÊµÏÖÀÏÄê³Õ´ôÖ¢°üÈÝÐÔÉç»áµÄŬÁ¦£¨½ØÖÁ2023Äê3ÔÂ31ÈÕ£¬45¸öÏØµÄ167¸öËùÔÚ£©¡£´ËÍ⣬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÕýÔÚÓë°üÂÞÎľ©Çø£¨2022²ÆÕþÄê¶È£©ÔÚÄ򵀮äËû46¸öµØ·½Õþ¸®ºÏ×÷¿ªÕ¹³Õ´ôÖ¢Ïà¹ØÏîÄ¿£¬Õë¶Ôµ±µØÎÊÌâÌṩÕë´óÄÔ½¡¿µÆÀ¹À»ú»á£¬²¢Íƶ¯½¨Á¢ºóÐøÒ½ÁÆ»¤ÀíºÍÖ§³Ö;¾¶µÄ¾Ù´ë¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾½«ÖÂÁ¦ÓÚ´´½¨ÕâÑùÒ»¸öÉçÇø£ºÔÚÕâ¸öÉçÇøÀÈËÃÇ¿ÉÒÔÔÚ½¡¿µ×´Ì¬ÏÂÁ˽âºÍ¼ì²é×Ô¼ºµÄ´óÄÔ½¡¿µÇé¿ö£¬¶øÇÒ¿ÉÒÔ¶Ô³Õ´ôÖ¢½øÐÐÔçÆÚ·¢ÏÖ¡¢Õï¶ÏºÍ×¼±¸£¬²¢ÊµÏÖÒ»¸ö³Õ´ôÖ¢°üÈÝÐÔÉç»á£¬ÈóմôÖ¢»¼ÕߺÍÈÕ³£Éú»îÁìÓòµÄÈËÃÇ¿ÉÒÔÆ¾¾Ý×Ô¼ºµÄÒâÔ¸Éú»î¡£

 

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

FDA×ÉѯίԱ»áÒ»ÖÂͶƱȷÈÏLEQEMBI?£¨lecanemab-irmb£©ÖÎÁư¢¶û´Äº£Ä¬²¡µÄÁÙ´²»ñÒæ

ÖÜΧºÍÖÐÊàÉñ¾­ÏµÍ³Ò©Îï×ÉѯίԱ»á»ùÓÚÔçÆÚ°¢¶û´Äº£Ä¬²¡»¼ÕߵĴóÐÍÈ«ÇòÑéÖ¤ÐÔIIIÆÚClarity ADÁÙ´²ÊÔÑéµÄÊý¾Ý½øÐбí¾ö¡£

×÷ΪÓÅÏÈÉóÆÀ£¬LEQEMBI´«Í³ÉóÅúPDUFAÐж¯ÈÕÆÚÒѶ¨ÔÚ2023Äê7ÔÂ6ÈÕ¡£

LEQEMBIÓÚ2023Äê1ÔÂ6ÈÕÔÚÃÀ¹úʳƷºÍÒ©Îï¹ÜÀí¾Ö¿ìËÙͨµÀÈ϶¨Ï»ñµÃÅú×¼£¬ÓÃÓÚÖÎÁÆÔçÆÚ°¢¶û´Äº£Ä¬²¡¡£

 

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡ÁªºÏÐû²¼£¬ÃÀ¹úʳƷºÍÒ©Îï¹ÜÀí¾Ö£¨FDA£©ÖÜΧºÍÖÐÊàÉñ¾­ÏµÍ³Ò©Îï×ÉѯίԱ»á£¨PCNS£©È«Æ±Í¨¹ý£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾IIIÆÚClarity ADÁÙ´²ÊÔÑéÊý¾Ý֤ʵÁËLEQEMBI?£¨lecanemab-irmb£©100 mg/mL×¢ÉäÒºÓÃÓÚ¾²ÂöÖÎÁư¢¶û´Äº£Ä¬²¡£¨AD£©µÄÁÙ´²»ñÒæ¡£´ËÍ⣬ίԱ»á³ÉԱȷÈÏÁËLEQEMBIµÄÕûÌå·çÏÕÐ§ÒæÇé¿ö¡¢Êý¾ÝµÄÁÙ´²ÒâÒ壬²¢ÌÖÂÛÁËÆäÔÚÌØ¶¨ÑÇ×éÖеÄÓ¦Ó㬰üÂÞÔØÖ¬ÂѰ×E£¨ApoE£©¦Å4ͬÐÍ»¼Õß¡¢ÐèҪͬʱʹÓÿ¹ÄýѪ¼ÁÖÎÁƵϼÕßÒÔ¼°ÄÔµí·ÛÑùѪ¹Ü²¡»¼Õß¡£

¶ÀÁ¢×¨¼ÒС×éµÄÒ»Ö¾ö¶¨ÊÇ»ùÓÚÔö²¹ÉúÎïÖÆ¼ÁÐí¿ÉÉêÇ루sBLA£©£¬ÆäÖаüÂÞÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÄ´óÐÍÈ«ÇòÑéÖ¤ÐÔIIIÆÚClarity ADÊÔÑéµÄÊý¾Ý¡£Clarity ADÊÔÑéµ½´ïÁËÆäÔ¤ÉèµÄÖ÷ÒªÖյ㣬±íÃ÷Óëο½å¼ÁÏà±È£¬18¸öÔÂÄÚÈÏÖªºÍ¹¦Ð§Ï½µµÄËٶȾßÓÐÏÔÖøÍ³¼ÆÑ§ÒâÒ壨27%£¬p=0.00005£©¡£¶ÔÓÚʹÓÃÆäËü¾­ÑéÖ¤µÄÁ¿±í¼ì²éÈÏÖªºÍ¹¦Ð§±ä»¯µÄ¶àÖØ¶ÔÕÕ´ÎÒªÖյ㣬ҲÊӲ쵽¾ßÓÐÏÔÖøÍ³¼ÆÑ§ÒâÒåµÄÖÎÁÆÐ§¹û¡£LEQEMBI×é×î³£¼ûµÄ²»Á¼Ê¼þ£¨>10%£©ÊÇÊäÒº·´Ó³£¨LEQEMBI£º26.4%£»Î¿½å¼Á£º7.4%£©¡¢ARIA-H£¨LEQEMBI£º17.3%£»Î¿½å¼Á£º9.0%£©£¬ARIA-E£¨LEQEMBI£º12.6%£»Î¿½å¼Á£º1.7%£©£¬Í·Í´£¨LEQEMBI£º11.1%£»Î¿½å¼Á£º8.1%£©ÒÔ¼°µøµ¹£¨LEQEMBl£º10.4%£»Î¿½å¼Á£º9.6%£©¡£ÊäÒº·´Ó³Ö÷ÒªÊÇÇá¶ÈÖÁÖжȣ¨1-2¼¶£º96%£©£¬²¢ÔÚµÚÒ»´ÎÓÃҩʱ·¢Éú£¨75%£©¡£Clarity ADÑо¿µÄ½á¹ûÔÚ°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©»áÒéÉÏÐû²¼£¬²¢Í¬Ê±·¢±íÔÚͬÐÐÆÀÉóµÄҽѧÔÓÖ¾¡¶ÐÂÓ¢¸ñÀ¼Ò½Ñ§ÔÓÖ¾¡·ÉÏ¡£

LEQEMBIÊÇÒ»ÖÖÕë¶Ô¾Û¼¯¿ÉÈÜÐÔ(¡°Ô­ÏËά¡±)ºÍ²»ÈÜÐÔµí·ÛÑùÂѰצ£¨A¦Â£©ÐÎʽµÄÈËÔ´»¯ÃâÒßÇòÂѰצÃ1£¨IgG1£©µ¥¿Ë¡¿¹Ì壬FDAÔÚ¿ìËÙͨµÀÈ϶¨ÏÂÅú×¼£¬²¢ÓÚ2023Äê1ÔÂ18ÈÕÔÚÃÀ¹úÉÏÊС £¿ìËÙͨµÀÏÂÅú×¼ÊÇ»ùÓÚIIÆÚÊý¾Ý£¬¸ÃÊý¾Ý±íÃ÷LEQEMBI¼õÉÙÁËA¦Â°ß¿éÔÚ´óÄÔÖеĻýÀÛ£¬ÕâÊÇADµÄÒ»¸ö¾ö¶¨ÐÔÌØÕ÷£¬Æä¼ÌÐøÅú׼ȡ¾öÓÚÔÚÈ·ÈÏÐÔµÄClarity ADÊÔÑ飨Ñо¿301£©ÖÐÑéÖ¤LEQEMBµÄÁÙ´²»ñÒæ¡£ ×ÉѯίԱ»áÒ»ÖÂͬÒ⣬Ñо¿301ÑéÖ¤ÁËÁÙ´²Òæ´¦¡£´¦·½Ò©Ê¹Ó÷ѷ¨°¸£¨PDUFA£©µÄ´«Í³Åú×¼Ðж¯ÈÕÆÚÊÇ2023Äê7ÔÂ6ÈÕ¡£

LecanemabµÄÈ«Çò¿ª·¢ºÍ¼à¹ÜÌá½»ÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ö÷µ¼£¬¶ø²úÎïÔòÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍÆ¹ã¡£ÆäÖУ¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÓµÓÐ×îÖÕ¾ö²ßȨ¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúËÕÖݹ¤³§Ë³Àûͨ¹ýÄÜÔ´¹ÜÀíÌåϵÈÏÖ¤

¾­ÖйúÖÊÁ¿ÈÏÖ¤ÖÐÐĵÄÉóºË£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ËÕÖݹ¤³§£¨ÒÔϼò³ÆÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúËÕÖݹ¤³§£©Ë³Àûͨ¹ýÁËGB/T23331-2020/ISO50001:2018ÄÜÔ´¹ÜÀíÌåϵÈÏÖ¤²¢È¡µÃÖ¤Ê飬±êÖ¾×ÅÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúËÕÖݹ¤³§ÄÜÔ´¹ÜÀíÌåϵ½¨ÉèÒÔ¼°Éú²ú½ÚÄܹÜÀíÔÚ¿ÆÑ§»¯¡¢¾«Ò滯¡¢³ß¶È»¯·½ÃæÈ¡µÃÁËÏÔÖø³ÉЧ¡£

ÔÚ¹ú¼Ò30/60̼Õþ²ßµÄÌᳫºÍÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾È«Çò30/40̼ÖкÍÒªÇóÏ£¬2022Äê8ÔÂÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúËÕÖݹ¤³§ÎªÁ˸üºÃµÄÍÆ¶¯¾«ÒæÉú²úºÍ½ÚÄܼõÅŽ¨Á¢ÁËÄÜÔ´¹ÜÀíС×飬Ïà¹Ø²¿ÃŶÔÕÕÄÜÔ´¹ÜÀíÌåϵ³ß¶ÈÈ«Ãæ½øÐвîÒì·ÖÎö£¬»ý¼«Öƶ¨ÄÜÔ´¸ÄÉÆ¼Æ»®£¬ÂäʵÍê³ÉÄÜÔ´¹ÜÀíÌåϵµÄ¸÷ÏîʵʩºÍÎļþÖÆ×÷¡£2023Äê3Ô£¬Íê³ÉÁËÖйúÖÊÁ¿ÈÏÖ¤ÖÐÐÄר¼ÒÍŶÓÉóºË£¬ÆÀÉóר¼ÒÍÅ¶Ó¸ß¶ÈÆÀ¼ÛÁËÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúËÕÖݹ¤³§ÔÚÄÜÔ´¹ÜÀí·½ÃæÈ¡µÃµÄ½á¹û£¬²¢Ë³Àûͨ¹ýÄÜÔ´¹ÜÀíÌåϵÈÏÖ¤£¬»ñµÃ¡¶ÄÜÔ´¹ÜÀíÌåϵÈÏÖ¤Ö¤Êé¡·¡£

ÀûÀ´w66(ÖйúÇø)_À´Àû¹ú¼ÊÆì½¢

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúËÕÖݹ¤³§½«ÒÔÄÜÔ´¹ÜÀíÌåϵÈÏ֤ΪÆõ»ú£¬Á¬ÐøÍƽøÉú²úµÄ¾«Ò滯ºÍÐ§Òæ»¯£¬Òýµ¼½¨ÉèÂÌÉ«¿ÉÁ¬ÐøÉú³¤¡°Áã̼¡±¹¤³§£¬Å¬Á¦¼ùÐÐhhc£¨human health care£©ÌåÌùÈËÀཡ¿µÆóÒµÀíÄ¸üºÃÌåÏÖÆóÒµµÄÉç»áÔðÈΡ£

ÍøÕ¾µØÍ¼